Categories: Health

VALNEVA Declaration of shares and voting rights: January 31, 2026

VALNEVA

Declaration of shares and voting rights
January 31, 2026
__________________________________________________________________________________________

Company name: VALNEVA
Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon
Regulated market of Euronext Paris – Compartment B

Declaration date: February 6, 2026

Number of shares
composing the share capital of Valneva
Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**
 

173,877,420

ordinary shares with a par value of €0.15 each

189,607,235 Double voting rights granted on 890 ordinary shares

Transfer into bearer form of 159,714 shares with double voting rights

Exercise of stock options resulting in the issuance of 337,675 new ordinary shares

Between January 8 & January 30, 2026

On January 9, 2026

Between January 12 & January 30, 2026

189,482,913

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
** Net (or exercisable at a General Meeting) voting rights.

GlobeNews Wire

Recent Posts

Xnergy’s PH Series Becomes World’s First 1.5KW Wireless Charger Certified To FCC, UL And CE Standards

SINGAPORE, June 9, 2026 /PRNewswire/ -- Xnergy Autonomous Power Technologies (Xnergy), a Singapore-headquartered leader in…

47 minutes ago

IEP – Record Conflicts Drive Peace to Historic Low as AI warfare surges

LONDON, June 9, 2026 /PRNewswire/ -- The 2026 Global Peace Index (GPI), released today by…

47 minutes ago

Harness Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinsons Research to Advance Parkinson’s Disease Programme

June 09, 2026 02:06 ET  | Source: Harness Therapeutics Grant awarded through the Parkinson's Disease…

2 hours ago

Idorsia strengthens financial position with up to CHF 250 million loan from Pharmakon

Ad hoc announcement pursuant to Art. 53 LR Senior secured term loan of up to…

2 hours ago

Rapid Nutrition Featured on CNBC Discussing Key Trends Shaping the Future of Consumer Wellness

CNBC interview explores GLP-1 weight loss adoption, clinically backed nutrition, preventative health and the evolving…

2 hours ago

A New Lease of Life: Stories of Hope, Survivorship and Second Chances with Apollo Hospitals

Cancer changes lives long before it changes medical reports.NEW DELHI , June 8, 2026 /PRNewswire/ --…

6 hours ago